If you answered yes to the above questions, consider joining the NN9500-7730 study.
What is the NN9500-7730 study?
In this clinical trial, we will investigate the effect of the study drugs involved, alone or in combination, on alcohol use and liver damage in people with alcohol-related liver disease. Previous studies have suggested that these medications may be beneficial for people with alcohol-related liver disease (ALD); however, more evidence is needed to determine if this is indeed the case.
What is ALD?
Alcohol-related liver disease (ALD) is caused by excessive alcohol consumption over time and may lead to a build-up of scar tissue in the liver. It is not known why some people develop ALD and others do not. However, it is known that the risk of developing ALD increases with the amount of alcohol consumed. ALD is a serious disease that, if left untreated, can progress and cause liver failure that can be fatal. ALD is difficult to spot because you may not experience symptoms until the disease is very advanced. Apart from stopping alcohol consumption entirely, there are currently only limited options to manage the disease.
You may be eligible to participate in the NN9500-7730 study if:
- you are 18 years of age or older
- you have had alcohol overuse for more than 5 years and drink more than three drinks (female) /four drinks (male) per day for the past year
- your doctor has told you that you have ALD
- you are available to receive two phone calls and attend 10 clinic visits over a period of 39 weeks.
Why should you participate?
You should participate in this clinical trial to:
- receive support to reduce your alcohol consumption
- take better care of your liver and improve understanding of your ALD
- obtain expert medical care at leading healthcare facilities
- help others by contributing to medical research.
Participating in a clinical study can improve future treatment options for you and other people with ALD.
For more information and to refer yourself for enrolment, please contact your nearest clinical site:
NSW
- St George Hospital – Nathan McGarry (nathan.mcgarry@health.nsw.gov.au)
- Holdsworth House Medical Centre – Professor Paul Haber, practicing in Royal Prince Alfred Hospital, Camperdown NSW 2050 (paul.haber@sydney.edu.au) or Jackson Thorne (Jackson.Thorne@holdsworthhouse.com.au)
- Westmead Hospital – Xiao Mei He (xiaomei.he1@health.nsw.gov.au) or Christine Gonzales (Christine.Gonzales@health.nsw.gov.au)
VIC
- Vincent’s Hospital Melbourne – Tamara Debreceni (tamara.debreceni@svha.org.au)
- Department of Gastroenterology & Hepatology, Monash University – Adele O’Brien (adele.obrien@monash.edu)
WA
- Fiona Stanley Hospital – Wendy Lam (wendy.lam@health.wa.gov.au) or Huirong (Claire) Ma (huirong.ma@health.wa.gov.au)
For more information about the Novo Nordisk clinical studies, visit www.novonordisk-trials.com
